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698Reduced-Intensity Allogeneic Stem Cell
Transplantation in Children and Young Adults
with Ultrahigh-Risk Pediatric Sarcomas
Kristin Baird,1 Terry J. Fry,1 Seth M. Steinberg,2
Michael R. Bishop,3 Daniel H. Fowler,3 Cynthia P. Delbrook,1 Jennifer L. Humphrey,4
Alison Rager,5 Kelly Richards,1 Alan S. Wayne,1 Crystal L. Mackall1Some subsets of pediatric sarcomapatients havevery poor survival rates.Wesought todetermine the feasibility
and efficacy of allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric sarcoma populations
with\25% predicted overall survival (OS). Patients with ultrahigh-risk Ewing’s sarcoma family of tumors
(ESFT), alveolar rhabdomyosarcoma, or desmoplastic small round cell tumors received EPOCH-fludarabine
induction, a cyclophosphamide/fludarabine/melphalan preparative regimen, and HLA matched related periph-
eral blood stem cells. Thirty patients enrolled; 7 did not undergo alloHSCT because of progressive diseasewith
diminishing performance status during induction. All 23 alloHSCTrecipients experienced rapid full-donor en-
graftment, with no peritransplantation mortality. Five of 23 alloHSCTrecipients (22%) remain alive (OS of 30%
by Kaplan-Meier analysis at 3 years), including 3 of 7 (42%) transplanted without overt disease (median survival
14.5 versus 29.0 months from alloHSCT for patients transplanted with versus without overt disease, respec-
tively). Among the 28 patients who progressed on the study, the median survival from date of progression was
1.9months for the 7who did not receive a transplant comparedwith 11.4months for the 21 transplanted (P5
.0003). We found prolonged survival after posttransplantation progression with several patients exhibiting
indolent tumor growth.Wealso saw several patientswith enhanced antitumoreffects fromposttransplantation
chemotherapy (objective response to pretransplantation EPOCH-F was 24% versus 67% to posttransplanta-
tion EOCH); however, this was associated with increased toxicity. This largest reported series of alloHSCT
in sarcomas demonstrates that alloHSCT is safe in this population, and that patients undergoing alloHSCT
without overt disease show higher survival rates than reported using standard therapies. Enhanced chemo-
and radiosensitivity of tumors and normal tissues was observed posttransplantation.
Biol Blood Marrow Transplant 18: 698-707 (2012) Published by Elsevier Inc on behalf of American Society for Blood and
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Approximately 25% of children and young adults
with newly diagnosed sarcomas have metastatic disease
at presentation, and long-term survival for these
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Among pediatric sarcoma patients with metastases,
patients with bone and bone marrow metastases
typically experience survival rates\25% [3-5]. Within
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(ESFT) and other risk factors can be identified that dem-
onstrate survival rates of\10% [3]. In metastatic rhab-
domyosarcoma (RMS), risk factors for very poor
survival include older age, alveolar histology, bone or
bone marrow involvement, unfavorable primary sites,
and 3 or more metastatic sites. Patients with.2 of these
risk factors have\15% overall survival (OS) [4,6]. Very
few pediatric sarcoma patients who experience poor
responses to front-line therapy, early recurrence
(within 12 months of completing front-line therapy)
[7,8], or multiple recurrences survive long term [9-11].
Patients with desmoplastic small round cell tumor
(DSRCT) have similarly poor outcomes, especially
those with metastatic or primary progressive disease
(PD) [12-14]. Thus, patients with ESFT or alveolar
rhabdomyosarcoma (aRMS) who have bone or bone
marrow metastases, early recurrence or primary PD,
and patients with metastatic or progressive DSRCT,
can be classified as ultrahigh risk, based upon long-
term survival rates of\25%.
High-dose therapy with autologous hematopoietic
stem cell rescue (autoHSCT) in patients with high-
risk sarcomas has been widely tested in single-arm
studies, without conclusive evidence for clinical
benefit [2,3,6,15-21]. Immune-mediated killing post-
alloHSCT provides antileukemic effects [22] and
allogeneic graft-versus-tumor (GVT) effects have
been observed in a variety of solid tumors including
breast [23,24], colon [25], renal [25,26], ovarian, and
pancreatic cancers [27]. Some case reports of reduced-
intensity alloHSCT in neuroblastoma, ESFT, and
RMShave suggested a possibleGVTeffect in these dis-
eases [28-33]. Historically, myeloablative allogeneic
hematopoietic stem cell transplant (alloHSCT) for
pediatric sarcomas was associated with significant
transplant-related mortality with rates of transplant-
related mortality up to 40% [34]. However, improve-
ments in supportive care and the introduction of
reduced-intensity conditioning regimens has made
alloHSCT safer, which may diminish toxicity and
improve outcomes in this heavily pretreated population
[34]. We sought to test the feasibility and efficacy of a
reduced-intensity alloHSCT-based regimen in a series
of patients with ultrahigh-risk pediatric sarcomas.MATERIALS AND METHODS
Enrollment and Eligibility
Eligible patients had ESFT or alveolar RMS in any
of the following categories: initial diagnosis with bone
or bone marrow metastases and enrolled after comple-
tion of standard front-line therapy (see Supplemental
Methods for details of acceptable standard front-line
therapy); progressive disease during standard front-
line therapy, tumor recurrence within 1 year aftercompleting standard front-line therapy, and enrolled
at the time of recurrence; second or subsequent recur-
rence. Patients with DSRCT were eligible if they had
unresectable or metastatic disease (extra-abdominal
and abdominal), progressive or persistent disease
with standard front-line therapy, or recurrence within
1 year of completing standard front-line therapy.
Eligibility was not affected by the presence or absence
of overt disease at the time of enrollment. The institu-
tional review board of the National Cancer Institute
approved this study, and all patients, or their guard-
ians, provided informed consent.Treatment Regimen
All patients received 1 to 3 cycles of pretransplanta-
tion immune-depleting ‘‘induction’’ chemotherapy
(EPOCH-F) every 21 days (previously described by
Bishopet al. [23]).Thegoal of the induction chemother-
apy was to reduce host T cells to facilitate rapid donor
engraftment and provide tumor control before proceed-
ing to transplantation. EPOCH-F consisted of:
etoposide, 50mg/m2 per day by continuous i.v. infusion
days 1 to 4; prednisone, 60 mg/m2 per day in 2 to 4 di-
vided doses orally on days 1 to 5; vincristine, 0.4 mg/
m2 per day by continuous i.v. infusion on days 1 to 4; cy-
clophosphamide, 750mg/m2 i.v. over 30minutes on day
5; doxorubicin, 10 mg/m2 per day by continuous i.v. in-
fusion days 1 to 4; fludarabine, 25 mg/m2 per day i.v.
over 30 minutes on days 1 to 3; and filgrastim (granulo-
cyte-colony stimulating factor [G-CSF]), 5 mg/kg per
day subqutaneously fromday6until absolute neutrophil
count.1000/mL 2 days. Initially, CD41 counts were
measured following each cycle and a target of \50
CD41 cells/mL was the determining factor of cycle
number up to amaximum of 3 cycles. Patients with pro-
gressive disease, however, were taken after recovery
from chemotherapy cycle regardless of cycle number
or CD41 count. However, because of brisk and sustain-
able engraftment, the protocol was later amended, such
that disease responsewas the primary determinant of cy-
cle number. Patients received 3 cycles of induction
EPOCH-F unless they developed progressive disease,
atwhich timedeterminationof eligibility for proceeding
to transplantation was based upon performance status
(patients withECOG3-4were removed from the study,
whereas patients with ECOG 0-2 were eligible to pro-
ceed to transplantation). Eligibility for transplantation
was not impacted by the presence of overt disease.
Transplantation commenced as soon as possible
following hematologic recovery from the final
EPOCH-F cycle. Transplant conditioning consisted
of: cyclophosphamide 1200 mg/m2/day on days 26
through 23; fludarabine 30 mg/m2/day and days 26
through 23; and melphalan 100 mg/m2 on day 22.
Grafts were G-CSF mobilized, unmodified peripheral
blood stem cells from 6 of 6 HLA-matched siblings
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collection of all donors during a single apheresis
procedure. Recipients received G-CSF (5 mg/kg/day)
until recovery of the absolute neutrophil count to
5000/mL  3 days.
Cohort 1 (n5 13) received single-agent cyclosporine-
A for graft-versus-host disease (GVHD) prophylaxis,
and a second cohort, cohort 2 (n5 10), received tacro-
limus plus sirolimus (see Supplemental Methods for
dosing). Where possible, donor lymphocyte infusions
(DLI) (CD3 dose range 5  10521  108/kg) were
administered to patients with disease recurrence and
no evidence of GVHD after discontinuation of
GVHD prophylaxis. Grading of acute GVHD
(aGVHD) was based on a modified Glucksburg Scale
[35], and the classic Seattle Criteria were used for
chronic GVHD (cGVHD) grading and scoring [36].
Statistical Analysis
Sample size was based on a Simon’s optimal phase
II trial design, with alpha 5 0.10 and 90% power, to
target an acceptable engraftment rate (.95% donor
engraftment at day 100 in .75% of patients) and to
rule out an unacceptably low engraftment rate of
50% (p1 5 0.75, p0 5 0.50) [37]. The study also
sought to measure clinical outcomes such as relapse-
free survival and OS. Survival was determined from
the on-study date until date of death or last follow-
up. When analyses are restricted to patients who
underwent alloHSCT, survival from date of transplan-
tation was reported. The probability of survival as
a function of time was determined by the Kaplan-
Meier method [38]. Log-rank tests were used to assess
the impact of various factors on the probability of sur-
vival for patients who underwent alloHSCT [39].
Other analyses, such as progression-free survival,
based on the time from on-study date until progression
or last follow-up, and survival following progression,
were performed. The association between patient co-
hort and grade or extent of GVHD was determined
by an exact Cochran-Armitage test [40]. All P values
are 2 tailed and reported without adjustment for mul-
tiple comparisons.RESULTS
Patient Characteristics, Pretransplantation
EPOCH-F
Between September 2002 and November 2008, 30
pediatric and young adult patients (median age 19,
range: 8-32 years) were enrolled. Clinical characteris-
tics of all patients are summarized in Table 1. Seven-
teen patients had ESFT, 7 had aRMS, and 6 had
DSRCT. Patients received a mean of 2.2 EPOCH-F
cycles/pt (median 3 cycles/patient) (Table 2). Immune
depletion was achieved as evidenced by a median CD4count of 0 cells/mL at the time of transplantation
(Figure 1). Pretransplantation EPOCH-F was well
tolerated. Of 66 EPOCH-F cycles administered
pretransplantation, there were 5 episodes of fever
and neutropenia in 4 patients and only 1 of 66 cycles
was associated with mucositis (Table 2).
All tumor response was based on RECIST criteria.
Four patients enrolled without evidence of disease and
all remained no evidence of disease (NED) during
EPOCH-F cycles. Of 26 patients enrolled with mea-
surable disease, 1 had a complete response (CR) fol-
lowing EPOCH-F with radiation therapy to sites of
disease before transplantation, and is thus inevaluable
for response to EPOCH-F. Among 25 patients evalu-
able for response to pretransplantation EPOCH-F,
there were 2 CR 4 partial response (PRs), 9 stable dis-
ease (SD), and 10 PD, for an overall objective response
rate of 24%. Among the 10 patients who experienced
PD during EPOCH-F, 7 had a rapidly diminishing
performance status because of disease progression
and were removed from study before alloHSCT,
whereas 3 proceeded to transplantation despite PD.Clinical Outcomes
Twenty-three patients underwent alloHSCT. The
transplantation regimen was well tolerated with no
peritransplantation mortality (within 100 days). Rapid
conversion to complete donor chimerismwas observed
in all patients (.95% chimerism in 22 of 23 by day
114, 22 of 22 by day128).Median time to reach an ab-
solute neutrophil count of 500/mm3 was 9 days (range:
8-12) and a platelet count of 50,000/mm3 was 15 days
(range: 10-43). Immune recovery was brisk and sus-
tained. CD4, CD8, and natural killer (NK) cell num-
bers levels approached or exceeded normal values by
day 128 (median CD41 count 284/mm3 on days
128-42), and B cell recovery reached normal values
by 6 months (Figure 1 and Supplemental Table).
Using an intent-to-treat analysis, median survival
from enrollment for all patients was 15.9 months
(range: 2.2-77.01 months, n 5 30), with a median
progression-free survival of 5.5 months from enroll-
ment (Figure 2A). The 7 patients who did not undergo
transplantation because of rapid PD had a median sur-
vival of 1.9 months from progression date and 3.3
months (range: 2.2-11.2) from enrollment. The 23 pa-
tients who received alloHSCT had a median survival
from enrollment of 19.1 months (range: 5.6-77.01)
and had a median survival of 16.9 months from their
date of transplantation. Two-year survival rates for
patients undergoing alloHSCT were 39.1% from
date of enrollment (Figure 2A) and 34.8% from date
of transplantation. Figure 2A is an illustration of sur-
vival from study enrollment for those transplanted
while on study and for those unable to proceed to
transplantation. As transplantation occurs months
Table 1. Demographic Information for All Patients Enrolled
Patient #
Age
(Years) Sex Diagnosis
High-Risk
Features
# Prior
Regimens
Disease Status
at Enrollment
Disease Status
at HSCT Cohort
Time to
Progression
(Days)
Survival
Post-HSCT
(Months)
Received SCT
1 20 M aRMS MR 5 PD PR I 100 34
2 19 M aRMS MR 3 PD PR I 42 4
3 10 F ESFT ER 2 PD PR I 28 4
4 14 F ESFT ER, B/BM, MR 3 PD SD I 100 6
6 18 F aRMS B/BM 2 PD SD I 100 15
8 20 M ESFT PP, B/BM 1 PD PD I 160 21
9 19 F aRMS MR 2 PD SD I 60 7
10 30 M ESFT B/BM 2 PD SD I 100 25
12 16 M aRMS B/BM 2 PD SD I 70 13
13 12 M aRMS MR 3 PD PD I 100 77+
14 19 F ESFT PP 1 PD SD I 42 75+
15 25 M ESFT MR 2 PD SD I 100 15
17 8 F ESFT ER 2 NED NED I NED 9b
18 25 M DSRCT Metastatic 2 SD CR(NED) II 150 45
20 18 M ESFT B/BM 3 PD PD II 38 4
21a 15 M ESFT B/BM 1 NED NED II NED 61+
22 21 M ESFT B/BM 1 PD PR II 100 19
24 14 M DSRCT Metastatic 2 NED NED II 300 48+
25 19 M aRMS MR 2 PD CR(NED) II 170 24
27 26 M DSRCT PP /Metastatic 1 PD CR(NED) II 100 39+
28a 14 F ESFT B/BM 1c NED NED II 271 17
29 32 M DSRCT Metastatic 2 PD SD II 237 17
30 23 M DSRCT Metastatic 1 PD SD II 180 10
Did Not Receive SCT
5 26 M ESFT ER, B/BM 2 PD PD
7 17 M ESFT PP, B/BM 1 PD PD
11 13 M ESFT ER 3 PD PD
16 28 F ESFT PP 2 PD PD
19 17 F ESFT ER 2 PD PD
23 15 F ESFT ER 4 PD PD
26 23 M DSRCT PP 3 PD PD
B/BM indicates bone or bone marrow metastases; CR, complete response; ER, early recurrence; MR, multiply recurrent; PD, progressive disease; PP,
primary progressive disease; SD, stable disease.
aAmong the 2 patients with ESFTenrolled in first remission, prognostic scores according to Ladenstein et al. were: 3.5 points due to bone marrow, lung,
multiple bone metastasis (patient #21) and 5.0 points due to lung, bone marrow, multiple bone, and large primary (patient #28).
bDeath in remission because of radiation-induced bronchiolitis obliterans.
cUp-front regimen included autologous stem cell transplantation.
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known at the time of enrollment, the survival time is
for both those transplanted and those not trans-
planted, and includes the time patients were receiving
lymphodepleting chemotherapy. At the time of last
follow-up, 22% (5 of 23) of transplanted patients are
alive with a median potential follow-up of 6.0 years.
Patients transplanted without overt evidence of dis-
ease had better survival outcomes than those trans-
planted with overt disease (median survival 29.0
versus 14.5 months from date of transplantation)
(Figure 2B). We detected no difference in survival
based upon high-risk features, as patients with multi-
ply recurrent tumors had similar survival rates com-
pared with patients with progressive or persistent
disease and those with high-risk metastatic disease
(Figure 2C). Although not statistically significant, pa-
tients transplanted with DSRCT had a longer median
OS from date of transplantation when compared with
patients with ESFT or RMS (23.8 months forDSRCT versus 15.8 months for ESFT versus 13.9
months for aRMS, respectively) (Figure 2D). We de-
tected no association among age, gender, or GVHD
prophylaxis and survival.
Definitive GVT effects (defined as tumor response
after day 42 posttransplantation without cytotoxic
therapy) were not observed, and DLI were adminis-
tered to 8 patients (1-7 doses), without objective evi-
dence for antitumor effects. However, despite early
posttransplantation relapse (median 100 days, range:
28-300 days), prolonged survival was experienced by
a subset of these patients (Table 1 and Figure 3).
Among the 28 patients who progressed on the study,
the median survival from date of progression was 1.9
months for the 7 who progressed during induction
and did not undergo alloHSCT compared with 11.4
months for the 21 alloHSCT recipients who pro-
gressed post transplant (P 5 .0003 for actuarial analy-
sis; Figure 3 presents a more detailed view by patient).
Thus, direct evidence for GVT effects were not
Table 2. Noninfectious Toxicity of Pre-HSCT EPOCH-F, Post-HSCT EOCH, and Post-HSCT Radiotherapy in Patients Undergoing
HSCT
Patient # Diagnosis
Recurrence
Post-HSCT
Pre-HSCT EPOCH-F Post-HSCT EOCH Post-HSCT Radiotherapy
Cycles
Best
Response Toxicity Cycles
Best
Response Toxicity Site Toxicity
1 aRMS Y 3 PR 6 CR G3 mucositis Chest wall G2 skin
2 aRMS Y 3 PR 1 PD Abdomen G4 GI
3 ESFT Y 3 PR Pancreas G4 LFTs,
G4 pancreatitis
4 ESFT Y 3 SD 1 PD G3 mucositis
6 aRMS Y 3 SD Pleura,
mediastinum
G4 LFTs
G2 mucositis
8 ESFT Y 1 PD G2 mucositis 5 VGPR G3 mucositis,
G3 esophagitis,
G3 liver toxicity
9 aRMS Y 1 SD Chest wall G4 skin,
G3 mucositis
10 ESFT Y 2 SD 9 PR G2 myalgias Spine, skull G2 nausea
+ vomiting,
G2 fatigue
12 aRMS Y 3 SD Pelvis G4 enteritis
13 aRMS Y 2 PD
14 ESFT Y 3 SD 6 PR Pulmonary
(cyberknife)
15 ESFT Y 3 SD 1 PD Brain G3 mucositis
17 ESFT N 3 NED Whole lung G3 mucositis,
G3 skin,
G5 lung
18 DSRCT Y 3 CR 10 PR G1 mucositis
20 ESFT Y 1 PD L arm,
R shoulder,
B/L femur
21 ESFT N 3 NED
22 ESFT Y 3 PR 2 PR G3 mucositis
24 DSRCT Y 1 NED 2 PD
25 aRMS Y 3 CR 6 CR
27 DSRCT Y 3 CR (with XRT) 8 VGPR
28 ESFT Y 1 NED
29 DSRCT Y 3 SD
30 DSRCT Y 3 SD
aRMS indicates alveolar rhabdomyosarcoma; B/L, bilateral; CR, complete response; DSRCT, desmoplastic small round cell tumor; ESFT, Ewings sarcoma
family of tumors; G1; grade 1, G2, grade 2; G3, grade 3; G4, grade 4; G5, grade 5; L, left; R, right; N, no; NED, no evidence of disease; PD, progressive
disease; PR, partial response; SD, stable disease; VGPR, very good partial response; XRT, radiotherapy; Y, yes.
Responses based on RECIST criteria; a VGPR is a >75% reduction in disease.
702 Biol Blood Marrow Transplant 18:698-707, 2012K. Baird et al.observed, but pretransplantation progression was asso-
ciated with rapid death in all patients, whereas pro-
longed survival occurred despite posttransplantation
disease progression in some patients.Figure 1. Immune recovery. Median cell count recovery of lymphocyte
subsets over time. The ‘‘Post’’ time point reflects cell counts following
EPOCH-F cycles. Day 0 reflects cell counts on the day of transplantation
following the preparative regimen, where effective immune depletion
was achieved and reflected by mean CD 4 counts of 0. Patients achieved
normal levels by 6months posttransplantation and sustained these levels
over time (norms are represented by dashed lines).Posttransplantation Response to Treatment and
Toxicity
We sought to evaluate potential causes for
prolonged survival despite early posttransplantation
disease progression. First, posttransplantation pro-
gression was accompanied by indolent tumor growth
in some cases as illustrated in Figure 4. Second, post-
transplantation progression was often responsive to
chemotherapy. All patients who relapsed received fur-
ther therapy, which was variable and included, but
not limited to: EOCH, irinotecan, radiation therapy,
and IGFR-1 antibody. Determination of chemother-
apy regimen was decided by multiple factors including
patient organ function, GVHD, and history of prior
therapy. The mostly commonly employed regimen
and one that allowed pre- and post-alloHSCTcompar-
ison was EOCH (fludarabine and prednisone were
eliminated to minimize potential impact on GVT ef-
fects). EPOCH-F was modified to EOCH and admin-
istered to 12 patients for posttransplantation disease
Figure 2. Clinical outcomes. Overall survival (OS) Kaplan-Meier survival curves are shown for: (A) all patients enrolled on study; showing patients who
were transplant and nontransplanted. (B)Comparisonof survival from transplantation forNEDpatients versus thosewith overt disease at transplantation
(P5.074). (C) Survival post-alloHSCT based upon high-risk clinical characteristics (P5NS). (D) Survival post-alloHSCT based upon histology (P5NS).
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transplantationEOCHwas substantial: 2CR, 6PR (in-
cluding 2 very good PRswith.75%disease reduction)
for an objective response rate of 67% to posttransplan-
tationEOCHcomparedwith a 24%objective response
rate to pretransplantation EPOCH-F. As shown in
Table 2, of 10 patients with disease evaluable for re-
sponse following pretransplantation EPOCH-F versus
posttransplantation EOCH, 4 (patients #1, 8, 10, andFigure 3. Prolonged survival despite early posttransplantation relapse. Surviv
not receiving alloHSCT (red) have short survivals following relapse, whereas tr
ing relapse. Patients in green represent surviving patients (only #21 has not rel
plantation lung irradiation.14) demonstrated enhanced chemoresponsiveness
posttransplantation, despite an equal or decreased
dose of the same cytotoxic agents.
The majority of patients also experienced greater
toxicity following posttransplantation EOCH than
was experienced with the EPOCH-F regimen, despite
the same or lower doses of cytotoxic drugs adminis-
tered posttransplantation. Mucositis was a common
and severe side effect, occurring in 5 of 12 patientsal (months) for individual patients are shown by horizontal bars. Patients
ansplanted patients (blue, green) experienced prolonged survival follow-
apsed). *Patient #17 died of bronchiolitis obliterans following posttrans-
Figure 4. Indolent growth of recurrent Ewing’s sarcoma following alloHSCT. Patient #15 showed persistent disease at the first posttransplantation
restaging (day 42). No systemic therapy was administered because of patient choice, and he showed minimal progression of disease over an
8-month period.
704 Biol Blood Marrow Transplant 18:698-707, 2012K. Baird et al.(3 grade 3, 1 grade 2, 1 grade 1) receiving posttrans-
plantation EOCH, whereas mucositis (grade 2) oc-
curred in only 1 of 30 patients receiving EPOCH-F
pretransplantation. Other toxicity following posttrans-
plantation EOCH included: presumed GVHD flares
of the skin, mouth, musculoskeleton, and liver; 20
documented infectious episodes in 6 patients, includ-
ing 7 pneumonias (4 viral, 2 fungal, and 1 bacterial), 3
bacteremias, and 2 episodes of cholecystitis, 1 of which
was associatedwith septic shock.Enhanced toxicitywas
not limited to EOCH chemotherapy, as 1 patient de-
veloped grade 3 mucosal toxicity and grade 4 skin tox-
icity in a site of previous radiation following a single
dose of gemcitabine chemotherapy (675 mg/m2). No-
tably, these toxicities were not associatedwith or attrib-
uted to increased hematologic toxicity, as reductions in
platelet count and absolute neutrophil counts were
similar following pretransplantation EPOCH-F and
posttransplantation EOCH (data not shown).
GVHD
High-grade aGVHD was not observed in cohort 1
(cyclosporine alone as GVHD prophylaxis), but 92%
(12 of 13) of patients developed grade 1-2 aGVHD,
and cGVHD occurred in all (12 of 12) evaluable
patients (Supplemental Figure). Chronic GVHD
manifestations were generally mild and easily treated,
but the near universal requirement for systemic immu-
nosuppression potentially limited GVT effects and
prevented administration of DLI. We therefore
sought to diminish the rate of GVHD in cohort 2 bymodifying the GVHD prophylaxis to tacrolimus and
sirolimus. The incidence of cGVHD in cohort 2 di-
minished to 50% (5 of 10), with 3 of 10 graded as ex-
tensive cGVHD and 2 of 10 graded as limited
cGVHD (Supplemental Figure). Thus, we observed
a significant reduction in the incidence of extensive
cGVHDwith tacrolimus/sirolimus compared with cy-
closporine A alone (P5 .0007). No deaths were attrib-
utable to GVHD in this series.DISCUSSION
Here we present the largest series of alloHSCT
undertaken for high-risk pediatric sarcomas. Several
conclusions can be drawn. First, although sarcoma
populations were reported to suffer high rates of peri-
transplantation mortality with traditional myelo-
ablative conditioning [41], our current regimen
accomplished rapid full-donor engraftment following
alloHSCT without peritransplantation mortality. Sec-
ond, median survival following alloHSCT appears
comparable to ultrahigh-risk pediatric sarcoma pa-
tients treated with standard salvage therapy, with
22% of patients (5 of 23) experiencing prolonged sur-
vival. Third, 42% of patients who underwent al-
loHSCT with no evidence of disease remain alive,
which is higher than is typically reported for this pop-
ulation. The favorable toxicity profile and promising
results for patients rendered NED before alloHSCT
provides a rationale for testing this approach in a larger
series of ultrahigh-risk sarcoma patients rendered
Biol Blood Marrow Transplant 18:698-707, 2012 705Allogeneic HSCT in Pediatric SarcomasNED, because this population has not seen advances in
clinical outcomes in the last 40 years.
Our clinical observations suggest that the
alloHSCT may have altered the natural history of
these very aggressive tumors. Tumor progression pre-
transplantation was associated with rapid demise,
whereas tumor progression posttransplantation was as-
sociated with more prolonged survival, which may re-
flect heretofore unappreciated interactions between
the immune milieu, tumor growth rates, and chemores-
ponsiveness. We saw clear evidence for increased che-
mosensitivity of both normal and tumor tissues
posttransplantation compared with that observed pre-
transplantation. Given that fludarabine and corticoste-
roids have no known antitumor effects against
pediatric sarcomas, the EPOCH-F versus EOCH regi-
mens would be expected to mediate equivalent antitu-
mor effects. However, in this series, we observed an
impressive chemotherapy response rate posttransplan-
tationof 67%, comparedwith a 24%response rate to es-
sentially the same regimen before transplantation. This
is an unexpected finding, because successive tumor re-
currences are typically associatedwith increased chemo-
resistance, especially to regimens that were previously
administered. Selection bias could contribute to these
observations, as those with the most aggressive disease
did not proceed to alloHSCT, but we also observed
enhanced antitumor responses posttransplantation in
4 individual patients, suggesting that the enhanced
chemotherapy response rate may be because of
alloHSCT-induced alterations in chemoresponsiveness.
Furthermore, chemotherapy and radiation were
also associated with enhanced toxicity, demonstrating
that cytotoxic effects on normal tissues were also mod-
ulated posttransplantation. The enhanced posttrans-
plantation chemotoxicity was manifested primarily as
mucositis and skin toxicity, without evidence for in-
creased myelosuppression. One patient died of bron-
chiolitis obliterans after receiving a total dose of 900
rads prophylactic whole-lung irradiation, a dose that
is usually well tolerated for prevention of lung metas-
tases in ESFT [42]. Zitvogel and coworkers have dem-
onstrated that immune-mediated events contribute to
the antitumor effects of radiotherapy and several cyto-
toxic agents, including doxorubicin as used here, are
associated with chemotherapy-induced calreticulin ex-
posure on tumor cells that augments innate immunity
[43,44]. More recently, work has also implicated IL-1
signaling in the antitumor effects of chemotherapy
[45].We postulate that immune priming because of al-
loreactivity effects result in both enhanced effects of
chemotherapy and/or radiation therapy targeting
both normal and tumor tissues. Regardless of the
mechanism, these clinical observations should serve
as a note of caution for clinicians treating patients
with cytotoxic agents after alloHSCT. Even very small
doses of radiation or chemotherapy can mediate unex-pected toxicity, resulting in substantial clinical
consequences. We avoid posttransplantation radiation
to visceral organs in our current trials and substantially
reduce the doses and dose intensity of cytotoxic regi-
mens. Our clinical observations suggest that if cyto-
toxic therapy is initiated with lesser doses and the
doses are increased gradually on subsequent cycles,
toxicity will be mitigated but clinical response may
be reduced as well (data not shown).
Although pretransplantation versus posttransplan-
tation tumor growth rates were not formally evaluated
in this study, our clinical observations demonstrated
that in some cases tumor recurrence was associated
with slow progression rates, even in the absence of cyto-
toxic therapy (Figure 4). It remains possible that
alloreactivity-mediated alterations in the immune mi-
lieumodulated tumor growth rates in this study. Indeed,
recent studies of immune-based therapies for prostate
cancer have demonstrated slower growth rates without
tumor shrinkage, which translate into prolongations in
OS, similar to the findings observed here [48-51]. It is
known that HLA class I antigens are expressed on
Ewing’s sarcoma, with reports that expression level
can vary with progression and depends on the site
[46,47]. Although the targets of allogeneic recognition
are not entirely clear, the favored hypothesis is
that minor histocompatibility mismatched antigens
expressed on tumor tissues serve as targets of an
allogeneic response in HLA-matched HSCT and may
produce some antitumor effects. Additionally, there is
in vivo evidence of NK cell tumor lysis in pediatric sar-
comas and evidence of allogeneicGVT effect in a single
patient following killer-immunoglobulin receptors
(KIR)-mismatched transplantation [52,53]. This data
suggests utilizing an approach potentiating NK cell
lysis via KIR-mismatch, or stem cell sources enriched
for NK populations may maximize GVT impact.
Using the transplant regimen presented here,
GVHD rates were substantial, although the severity
of GVHD was modest. In this nonrandomized se-
quential series, we saw a significant decrease in the
rate of cGVHDwith the addition of sirolimus to a cal-
cineurin inhibitor. These results are consistent with
anti-GVHD activity of sirolimus reported by Cutler,
Antin, and colleagues [54]. In some series, the inci-
dence of transplant-associated microangiopathy was
increased with the combined regimen [55]. However,
we observed transplant-associated microangiopathy
in only 1 patient who had previously received total
body irradiation for autoHSCT. Although sirolimus
has been reported to have preclinical and clinical activ-
ity in sarcomas [56] and one could postulate that po-
tential antitumor effects could impact outcomes, we
could discern no evidence of antitumor activity with si-
rolimus in this study, and the cohort of patients receiv-
ing sirolimus did not experience diminished tumor
recurrence compared with those treated without
706 Biol Blood Marrow Transplant 18:698-707, 2012K. Baird et al.sirolimus. Thus, the addition of sirolimus to this regi-
men did not result in any apparent increase in tumor
control, but sirolimus did significantly reduce the inci-
dence of GVHD.
In summary, we provide evidence that reduced
intensity alloHSCT can be safely administered to pa-
tients with ultrahigh-risk pediatric sarcomas. Patients
with ultrahigh-risk sarcomas rendered into a state of
no evident disease before alloHSCT experienced
higher survival rates than previously reported in this
population, raising the prospect that alloHSCT should
be tested in a larger series of these patients. The results
for patients who received alloHSCT in the presence of
overt disease are also of interest, as they suggest that
alloHSCT may have altered the natural history and/
or chemoresponsiveness of this group of very aggres-
sive tumors. Clinicians caring for patients treated in
this manner need to be aware of the potential for en-
hanced toxicity when cytotoxic agents are used follow-
ing alloHSCT, and future studies are needed to more
fully investigate whether chemoresponsiveness can be
altered by changing the immunologic milieu.
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